Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Infant, Newborn, Maternal Outcome
Phase NA
Enrollment 128
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

In this prospective controlled study, it was aimed to examine the effects of half swaddling in term infants on infant sleep routine, maternal sleep quality and postpartum depression.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: The Half Swaddling Application — Half swaddling application in term babies

Primary Outcomes

  • Follow-up telephone interview will be conducted at 0 (first interview), 1st, 2nd and 3rd months (Postpartum first 3 months)
  • Pittsburgh Sleep Quality Index (up to 3 months)
  • Edinburgh Postnatal Depression Scale (up to 3 months)
  • Short Infant Sleep Routine Questionnaire (up to 3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-05-18
Completion: 2025-12-15
Eligibility
Age: 18 Years – 45 Years
Sex: FEMALE
Volunteers: true
Enrollment: 128 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tanta University
Contact Information
Study Contact:
Hatice Kahyaoglu Sut, 1.
05337662979
haticesut@yahoo.com
Interventions
  • Behavioral: The Half Swaddling Application — Half swaddling application in term babies
Study Locations (1 sites)
Trakya University, Edirne, None Selected 22030 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * 18-45 years old, * Term birth (single birth over 37 weeks), * After an uncomplicated pregnancy process, the delivery was completed by normal vaginal or cesarean delivery method, * Not using cigarettes, alcohol and stimulants, * BMI\<30, * Not working on night shift, * Stable vital signs, * Those who have not received infertility treatment, * Do not have a chronic disease (such as hypertension, diabetes mellitus), * Not experiencing serious depression, anxiety and stress, * Not having any organic or non-organic disease that can cause cognitive impairment (such as Delirium, Dementia, Intellectual Retardation, etc.), * No serious maternal complications, * Mothers who volunteered to participate in the study will be included in the study. For baby; * Birth weight over 2500 g, * Stable vital signs, * APGAR score above 7, * No serious neonatal complications, * Midwives without congenital malformations will be included in the study. Exclusion Criteria: * under 18 years old, * Preterm birth (under 37 weeks and/or multiple births), * Incomplete delivery by normal vaginal or cesarean delivery method after a complicated pregnancy process, * Using cigarettes, alcohol and stimulants, * BMI\>30, * Working night shift, * No stable vital signs, * Having received infertility treatment, * Having a chronic disease (such as hypertension, diabetes mellitus), * Experiencing severe depression, anxiety and stress, * Having any organic or non-organic disease that can cause cognitive impairment (such as Delirium, Dementia, Intellectual Retardation, etc.), * Serious maternal complication, * Mothers who do not volunteer to participate in the study will not be included in the study. For baby; * Birth weight of 2500 g and below, * No stable vital signs, * APGAR score below 7, * Serious neonatal complication, * Babies with congenital malformations will not be included in the study.
Conditions Depression - Major Depressive Disorder, ...
Phase PHASE1
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to test a meditative neurofeedback intervention for depressed mood.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Behavioral: MediNF — Over 5-sessions participants will engage in a breath-focused meditative practice with frontal brain connectivity neurofeedback provided to enhance performance.
  • Behavioral: ShamMediNF — Over 5-sessions participants will engage in a breath-focused meditative practice with frontal brain connectivity neurofeedback provided that is yoked to a closely-matched individual in the experimental arm.

Primary Outcomes

  • Change in FCz-FC4 alpha band coherence (iCoh) (8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2024-11-15
Completion: 2027-11-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, San Diego
Contact Information
Study Contact:
Jyoti Mishra, PhD
858-621-1517
braine@ucsd.edu
Jyoti Mishra
858-621-1517
braine@ucsd.edu
University of California San Diego
Interventions
  • Behavioral: MediNF — Over 5-sessions participants will engage in a breath-focused meditative practice with frontal brain connectivity neurofeedback provided to enhance performance.
  • Behavioral: ShamMediNF — Over 5-sessions participants will engage in a breath-focused meditative practice with frontal brain connectivity neurofeedback provided that is yoked to a closely-matched individual in the experimental arm.
Study Locations (1 sites)
University of California San Diego, La Jolla, California 92093 United States
Eligibility Criteria
Inclusion Criteria: * moderate depression per PHQ9 symptom ratings Exclusion Criteria: * active substance abuse/dependence * psychotic disorders * bipolar disorder * displaying acutely suicidal behaviors
Conditions Anorexia Nervosa, Stress
Phase Not Applicable
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

EXCENTRICC is a platform for scientific collaboration between different disciplines, all working on a common theme: adrenocortical hormones. In this EXCENTRICC sub-study, associations are studied between cortisol levels and depression, anxiety, disease severity and hippocampal and insula volume in the brain in anorexia nervosa.

Design

Study type: Observational Observational model: Case Control Time perspective: Cross Sectional

Primary Outcomes

  • Hippocampus total volumen (cm3) (Cross sectional (AN patients during a treatment course))
  • Insula total volumen (cm3) ((AN patients during a treatment course))
  • Plasma cortisol level (mmol/l) (AN patients during a treatment course at any time in relation to the duration of the illness and course of treatment.)
  • Cortisol diurnal excretion (nmol/d) (AN patients during a treatment course at any time in relation to the duration of the illness and course of treatment.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-09-01
Completion: 2026-12-01
Eligibility
Age: 18 Years – 50 Years
Sex: FEMALE
Volunteers: true
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Odense University Hospital
Collaborators: Ruhr University of Bochum, Umeå University
Principal Investigators:
  • René K Støving, PhD (PRINCIPAL_INVESTIGATOR) - Odense University Hospital
Contact Information
Study Contact:
René K Støving, PhD
65411710
rene.stoeving@rsyd.dk
René K Støving, PhD
65411710
rene.stoeving@rsyd.dk
Odense University Hospital
Interventions
N/A
Study Locations (1 sites)
Odense University Hospital, Odense, 5000 Denmark
Eligibility Criteria
Inclusion Criteria: 1. Women who fulfill the criteria for AN according to the Diagnostic and Statistical Manual of Mental Disorders (DSM), version 5 (APA, 2013). 2. BMI \< 16. Exclusion Criteria: 1. Current treatment with glucocorticoids. 2. Current use of oral contraceptives. 3. Unstable acute somatic comorbidity, e.g., infection. 4. Any kind of metal prostheses or -implants.
Conditions Posttraumatic Stress, Depression, Anxiet...
Phase NA
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

This study evaluates two Internet-delivered cognitive behavioural therapy (ICBT) interventions: one for symptoms of posttraumatic stress disorder (PTSD) and one for symptoms of anxiety, depression, and PTSD. Both interventions have been tailored for Canadian public safety personnel (PSP). Outcomes of interest include preference for disorder-specific or transdiagnostic care, engagement with the interventions, changes in symptoms and functioning, and strengths and limitations of implementing ICBT with Canadian PSP.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: PSP PTSD Course — A tailored ICBT intervention designed to treat symptoms of PTSD will be delivered to public safety personnel. Clients will be offered once a week support, but support can be increased to twice a week support if PSP request extra support. The intervention is designed to be completed in 8 weeks, but clients will be able to extend their treatment by an additional 8 weeks (i.e., up to 16 weeks in total).
  • Behavioral: PSP Wellbeing Course — A tailored ICBT intervention designed to treat symptoms of depression, anxiety, or PTSD will be delivered to public safety personnel. Clients will be offered once a week support, but support can be increased to twice a week support if PSP request extra support. The intervention is designed to be completed in 8 weeks, but clients will be able to extend their treatment by an additional 8 weeks (i.e., up to 16 weeks in total).

Primary Outcomes

  • Change in posttraumatic stress (screening and 8, 26, and 52 weeks (note: as of December 2024, we are no longer collecting data at 52 weeks).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2020-07-06
Completion: 2028-03-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Regina
Collaborators: Government of Canada
Principal Investigators:
  • Heather D Hadjistavropoulos, PhD (PRINCIPAL_INVESTIGATOR) - University of Regina
Contact Information
Study Contact:
Heather D Hadjistavropoulos, PhD
306-585-5133
heather.hadjistavropoulos@uregina.ca
Heather D Hadjistavropoulos, PhD
306-585-5133
heather.hadjistavropoulos@uregina.ca
Department of Psychology and Collaborative Centre for Justice and Safety
Heather D Hadjistavropoulos, PhD
Department of Psychology and Collaborative Centre for Justice and Safety
Interventions
  • Behavioral: PSP PTSD Course — A tailored ICBT intervention designed to treat symptoms of PTSD will be delivered to public safety personnel. Clients will be offered once a week support, but support can be increased to twice a week support if PSP request extra support. The intervention is designed to be completed in 8 weeks, but clients will be able to extend their treatment by an additional 8 weeks (i.e., up to 16 weeks in total).
  • Behavioral: PSP Wellbeing Course — A tailored ICBT intervention designed to treat symptoms of depression, anxiety, or PTSD will be delivered to public safety personnel. Clients will be offered once a week support, but support can be increased to twice a week support if PSP request extra support. The intervention is designed to be completed in 8 weeks, but clients will be able to extend their treatment by an additional 8 weeks (i.e., up to 16 weeks in total).
Study Locations (1 sites)
Department of Psychology and Collaborative Centre for Justice and Safety, Regina, Saskatchewan S4S 0A2 Canada
Eligibility Criteria
Inclusion Criteria: * 18 years of age or older * residing in Saskatchewan for the duration of the intervention * endorsing symptoms of post-traumatic stress * able to access a computer and internet service * willing to provide a physician as emergency contact Exclusion Criteria: * high suicide risk * suicide attempt or hospitalization in the last year * primary problems with psychosis, alcohol or drug problems, or mania * currently receiving regular psychological treatment * concerns about ICBT
Conditions Premenstrual Dysphoric Disorder (PMDD)
Phase Not Applicable
Enrollment 15
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to assess the knowledge, perceptions and practices of occupational physicians regarding premenstrual dysphoric disorder (PMDD), a condition with significant occupational impact that remains insufficiently explored in occupational health.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Primary Outcomes

  • Knowledge and perceptions of occupational physicians regarding PMDD (During data collection period in 2026)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-03-09
Completion: 2027-03-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 15 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Strasbourg, France
Contact Information
Study Contact:
Sébastien WEIBEL, MD, PhD
33 3 88 11 51 57
sebastien.weibel@chru-strasbourg.fr
Sébastien WEIBEL, MD, PhD
Service de Psychiatrie 2 - CHU de Strasbourg - France
Clémentine RAGONDET, MD
Service de Psychiatrie 2 - CHU de Strasbourg - France
Interventions
N/A
Study Locations (1 sites)
Service de Psychiatrie 2 - CHU de Strasbourg - France, Strasbourg, 67091 France
Eligibility Criteria
Inclusion Criteria: * Occupational physicians or occupational health collaborators * Practicing in France for at least two years * Agreeing to participate in the study Exclusion Criteria: * Lack of proficiency in the French language
Conditions Trauma-related Mental Health Symptoms
Phase NA
Enrollment 36
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

The current proposal aims to refine and examine an intervention called Calm Moms. Calm Moms is a web-based treatment program designed to reduce anxiety, stress, and low mood symptoms among pregnant Veterans with a history of trauma exposure. Its contents are based on empirically supported cognitive behavioral therapy (CBT) techniques shown to be effective in reducing these symptoms. Further, the Calm Moms program is tailored towards the unique concerns of pregnant women and incorporates information on how to cope with and reduce the impact of trauma. Calm Moms may benefit pregnant Veterans by reducing their anxiety, stress, and low mood symptoms. Additionally, pregnant Veterans who engage in Calm Moms may have improved functioning, reduced impairment during pregnancy, and show increased interest and engagement with additional mental health care. The current proposal also aims to collect information regarding implementation of Calm Moms at additional sites, which will allow Calm Moms to impact a larger group of pregnant Veterans.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Behavioral: Calm Moms-V — Calm Moms-V is the trauma-informed treatment developed and refined by the PI and being tested in the current study. Calm Moms-V is an online treatment program for trauma-exposed pregnant Veterans designed to target anxiety, stress, low mood, and trauma-related symptoms using empirically supported CBT techniques. Calm Moms-V includes four sessions and a booster session closer to delivery/postpartum. Sessions 1-4 are designed to be completed across four weeks (one session delivered each week). Each session is self-paced and designed to take approximately 45 minutes to complete.
  • Behavioral: Care As Usual — The control condition will be Care As Usual (CAU). CAU at SLVHCS involves participation in available services chosen by the patient with input from their providers. Further, for all pregnant Veterans that use VHA maternity benefits, CAU includes routine phone calls (throughout pregnancy and up to one-year postpartum) conducted by the site MCC to coordinate maternity benefits, facilitate additional services, and arrange for specific supplies (e.g., breast pump). Further, the SLVHCS MCC mails each pregnant Veteran enrolled in VHA a "welcome packet" that includes national, local, and VHA MH and physical health resources that may be useful to them during the perinatal period. Veterans in the CAU condition will be assessed at the same intervals as those in the active condition.

Primary Outcomes

  • Acceptability of Intervention Measure (AIM) (Aim 2 at one-month follow-up and at three-month follow-up.)
  • Feasibility of Intervention Measure (FIM) (Aim 2 at one-month follow-up and at three-month follow-up.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-30
Completion: 2030-03-29
Eligibility
Age: Not reported
Sex: FEMALE
Volunteers: false
Enrollment: 36 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: VA Office of Research and Development
Principal Investigators:
  • Mary E Shapiro, PhD MS (PRINCIPAL_INVESTIGATOR) - Southeast Louisiana Veterans Health Care System, New Orleans, LA
Contact Information
Study Contact:
Mary E Shapiro, PhD MS
(504) 507-2000
mary.shapiro1@va.gov
Mary E Shapiro, PhD MS
(504) 507-2000
mary.shapiro1@va.gov
Southeast Louisiana Veterans Health Care System, New Orleans, LA
Mary E Shapiro, PhD MS
Southeast Louisiana Veterans Health Care System, New Orleans, LA
Interventions
  • Behavioral: Calm Moms-V — Calm Moms-V is the trauma-informed treatment developed and refined by the PI and being tested in the current study. Calm Moms-V is an online treatment program for trauma-exposed pregnant Veterans designed to target anxiety, stress, low mood, and trauma-related symptoms using empirically supported CBT techniques. Calm Moms-V includes four sessions and a booster session closer to delivery/postpartum. Sessions 1-4 are designed to be completed across four weeks (one session delivered each week). Each session is self-paced and designed to take approximately 45 minutes to complete.
  • Behavioral: Care As Usual — The control condition will be Care As Usual (CAU). CAU at SLVHCS involves participation in available services chosen by the patient with input from their providers. Further, for all pregnant Veterans that use VHA maternity benefits, CAU includes routine phone calls (throughout pregnancy and up to one-year postpartum) conducted by the site MCC to coordinate maternity benefits, facilitate additional services, and arrange for specific supplies (e.g., breast pump). Further, the SLVHCS MCC mails each pregnant Veteran enrolled in VHA a "welcome packet" that includes national, local, and VHA MH and physical health resources that may be useful to them during the perinatal period. Veterans in the CAU condition will be assessed at the same intervals as those in the active condition.
Study Locations (1 sites)
Southeast Louisiana Veterans Health Care System, New Orleans, LA, New Orleans, Louisiana 70119 United States
Eligibility Criteria
Inclusion Criteria: * Pregnant (any trimester) * Endorse a DSM-5-TR Criterion A traumatic event as indexed by the trauma exposure portion of the PTSD screen for primary care (PC-PTSD-5) * Endorse clinically elevated anxiety (as indexed by a total score of \> 3 on the GAD-2) or depression symptoms (as indexed by a total score of \> 3 on the PHQ-2) * Able to participate in an online intervention (i.e., have internet and smartphone, tablet, or computer access) Of note, pregnant Veterans will still be eligible if they are in concurrent psychotherapy and/or using psychotropic medications. Exclusion Criteria: * Evidence of a significant mental illness that would impede completion of the intervention * (i.e., active psychosis, uncontrolled bipolar disorder, a severe alcohol/substance use disorder, or suicidal ideation or behavior that requires immediate hospitalization or treatment) Evidence of a significant mental illness will be determined via pre-enrollment chart review.
Conditions Depression, Depression Disorder, Depress...
Phase NA
Enrollment 168
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn whether the dietary supplement GynMDD, when taken as an add-on to supportive psychotherapy, can improve symptoms of mild to moderate depression in adults aged 18 to 65. The main questions it aims to answer are: Does adding GynMDD to supportive psychotherapy lead to a greater reduction in depressive symptoms (measured by the MADRS scale) compared with supportive psychotherapy plus placebo? Does the supplement also improve digestive well-being and influence gut microbiota profiles over the course of treatment? Researchers will compare patients receiving supportive psychotherapy + GynMDD to those receiving supportive psychotherapy + placebo to see if GynMDD provides additional benefits beyond standard care. Participants will: * Attend regular appointments with their general practitioner * Complete one supportive psychotherapy session per week for 8 weeks * Take a daily dose of GynMDD or placebo * Complete weekly self-assessment questionnaires on mood, digestive symptoms, and any side effects via a mobile app * Provide two stool samples (at the start and end of the study) for microbiota analysis

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Dietary Supplement: GynMDD — Dietary Supplement: GynMDD (Sorolys®) Daily 2.5 g stick for 8 weeks Includes L-glutamine, Cavacurmin®, and Lacticaseibacillus rhamnosus GG
  • Other: Placebo — Placebo for 8 weeks Identical stick without active ingredients; β-carotene added for color

Primary Outcomes

  • Change in MADRS Score (Baseline (V0) to Week 8 (V2))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-24
Completion: 2027-11
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 168 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fondation FondaMental
Collaborators: GYNOV
Principal Investigators:
  • Marion LEBOYER, Pr (STUDY_CHAIR) - Fondation FondaMental
  • FAUCHER Pierre, Dr (STUDY_DIRECTOR) - GYNOV
Contact Information
Study Contact:
Clinical Project Manager
+3314981326
michelle.haddad@fondation-fondamental.org
Clinical Operation Director
florence.mahe@fondation-fondamental.org
swing@fondation-fondamental.org
Hôpital Albert Chenevier 40 rue de Mesly
Interventions
  • Dietary Supplement: GynMDD — Dietary Supplement: GynMDD (Sorolys®) Daily 2.5 g stick for 8 weeks Includes L-glutamine, Cavacurmin®, and Lacticaseibacillus rhamnosus GG
  • Other: Placebo — Placebo for 8 weeks Identical stick without active ingredients; β-carotene added for color
Study Locations (1 sites)
Hôpital Albert Chenevier 40 rue de Mesly, Créteil, 94010 France
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 to 65 years, inclusive * The main reason for consultation is a suspected depressive episode * MADRS score between 15 and 34, indicating mild to moderate depression * No suicidal risk, defined as a score of 0 on item 10 of the MADRS scale * Body Mass Index (BMI) between 19 and 29 (inclusive) * Signed informed consent, confirming that the participant understands the purpose and requirements of the study and agrees to comply with the procedures (including scheduled supportive psychotherapy sessions) * Affiliation with the French national health insurance system or beneficiary of such coverage Exclusion Criteria: * History of severe psychiatric disorders or currently undergoing supportive psychotherapy * Confirmed suicidal risk, defined as a score between 1 and 6 on MADRS item 10 * Current treatment with antidepressants (AD) * MADRS score \> 34 * Conditions in which probiotic administration is not recommended (e.g., immunodeficiency, presence of a venous catheter) * Allergy to any component of the placebo or the GynMDD dietary supplement * Current consumption of probiotic-based dietary supplements * Recent infectious episodes that may require antibiotic therapy * Current treatment with anxiolytics * Long-term chronic anti-inflammatory treatment * Alcohol abuse, defined as a consumption of 10 standard drinks per week or more * Use of illicit drugs or substances of abuse * Inability to provide informed consent * Participation in another clinical study within the past 12 months * Pregnant or breastfeeding women * Patients without health insurance * Individuals under legal protection, guardianship, trusteeship, or any other protective measure
Conditions Pancreatic Tumor, Benign, Pancreatic Can...
Phase Not Applicable
Enrollment 320
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective, observational cohort study (MIND-PANC) to explore the associations of chronic psychological stress with disease progression, treatment outcomes, and prognosis of pancreatic cancer. Researchers will ask participants to fill out simple questionnaires about their mood, worries, and sleep at the start of the study and at regular follow-up visits. The study will also collect a small blood sample (leftover from routine care) to measure stress-related markers. Investigators hypothesize that pancreatic cancer patients who have higher levels of ongoing psychological stress (such as anxiety, depression, or poor sleep) tend to have shorter survival times, a higher chance of recurrence, and a poorer response to treatment, compared to patients with lower stress levels.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • overall survival (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-05-11
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 320 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shanghai Zhongshan Hospital
Collaborators: First Affiliated Hospital Xi'an Jiaotong University, The Third Xiangya Hospital of Central South University
Contact Information
Study Contact:
Liang Liu
18017317395
liu.liang@zs-hospital.sh.cn
Zhongshan Hospital Affiliated to Fudan University
Interventions
N/A
Study Locations (3 sites)
the Third Xiangya Hospital of Central South University, Changsha, Hunan China
Zhongshan Hospital Affiliated to Fudan University, Shanghai, Shanghai Municipality China
The First Affiliated Hospital of Xi'an Jiao Tong University, Xi’an, Shanxi China
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years. * Histologically or cytologically confirmed diagnosis of pancreatic cancer, or other pancreatic diseases. * Conscious, with basic reading/writing or communication skills, able to understand and complete the questionnaire assessments (either independently, with assistance from research staff, or with help from a family member). * Voluntarily agree to participate in this study and sign a written informed consent form. Exclusion Criteria: * Presence of severe cognitive impairment (e.g., dementia, disturbance of consciousness) or a definite history of psychiatric disorders, judged by the investigator as unable to comply with the study assessments, and without a family member who can help complete the questionnaire assessments. * Presence of other severe, uncontrolled systemic diseases (e.g., severe heart, lung, or kidney failure), with an estimated life expectancy \< 3 months as judged by the investigator. * Inability to understand Chinese or presence of severe visual/hearing impairment that affects completion of the questionnaire assessments, and without a family member who can help complete the questionnaire assessments.
Conditions Depression - Major Depressive Disorder, ...
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

The RESPOND trial explores the link between early life adversity and later life depressive symptoms. The investigators have designed a new psychological therapy tailored to address the symptoms that can be caused by difficult experiences in early life. These symptoms include low mood, emotional dysregulation, and distressing thoughts and beliefs related to difficult or traumatic experiences. The investigators would like to see if this new therapy helps people feel better. The investigators are also studying the biological changes that can occur as a result of early life adversity, and how this therapy may influence those changes. To do this, the investigators ask questions about participants' physical and mental health and take blood samples.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Psychotherapy — Session 1 - Psychoeducation: Introductions + information about adversity and depression Session 2 - Behavioural Activation: Identify activation targets, create Daily Activities Schedule Session 3 - Identifying Emotions: Describe + label emotions; cycle of emotions Session 4 - Distress Tolerance: STOP + TIP skills Session 5 - Distress Tolerance: Self-soothing + improving the moment Session 6 - Stuck Points: Stuck points + impact statements Session 7 - Self-blame Beliefs: Negative self schemas; alternative thoughts worksheet Session 8 - Safety + Trust: Schemas of emotional safety and trust about self and others Session 9 - Power + Control: Stuck points related to scope of influence over events + the world Session 10 - Esteem: Reconstruct ideas of self; engaging positively with others Session 11 - Intimacy: Develop self- and other intimacy behaviours Session 12 - Wrap-up: Review new impact statements; revisit behavioural chang

Primary Outcomes

  • Montgomery and Asberg Depression Rating Scale (MADRS) (Baseline (week 0), Treatment endpoint (week 12), Follow-up (3 months post treatment))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-25
Completion: 2028-08-15
Eligibility
Age: 18 Years – 65 Years
Sex: FEMALE
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: St. Joseph's Healthcare Hamilton
Collaborators: Sun Life Financial Movement Disorders Research and Rehabilitation Centre
Principal Investigators:
  • Benicio Frey, MD, PhD (PRINCIPAL_INVESTIGATOR) - St. Joseph's Healthcare Hamilton
  • Sheryl Green, PhD (PRINCIPAL_INVESTIGATOR) - St. Joseph's Healthcare Hamilton
  • Jenna Boyd, PhD (PRINCIPAL_INVESTIGATOR) - St. Joseph's Healthcare Hamilton
Contact Information
Study Contact:
Katerina Dikaios, MSc
905 522 1155
dikaiosk@mcmaster.ca
Katerina Dikaios, MSc.
9028779750
dikaiosk@mcmaster.ca
St. Joseph's Healthcare Hamilton
Interventions
  • Other: Psychotherapy — Session 1 - Psychoeducation: Introductions + information about adversity and depression Session 2 - Behavioural Activation: Identify activation targets, create Daily Activities Schedule Session 3 - Identifying Emotions: Describe + label emotions; cycle of emotions Session 4 - Distress Tolerance: STOP + TIP skills Session 5 - Distress Tolerance: Self-soothing + improving the moment Session 6 - Stuck Points: Stuck points + impact statements Session 7 - Self-blame Beliefs: Negative self schemas; alternative thoughts worksheet Session 8 - Safety + Trust: Schemas of emotional safety and trust about self and others Session 9 - Power + Control: Stuck points related to scope of influence over events + the world Session 10 - Esteem: Reconstruct ideas of self; engaging positively with others Session 11 - Intimacy: Develop self- and other intimacy behaviours Session 12 - Wrap-up: Review new impact statements; revisit behavioural chang
Study Locations (1 sites)
St. Joseph's Healthcare Hamilton, Hamilton, Ontario L8P 3R2 Canada
Eligibility Criteria
Inclusion Criteria: * Adults 18 years old or older * At or above 18 on HAM-D, indicative of moderate-severe depressive symptoms * Any childhood (before 18 years old) adversity as indicated by scores on the CECA q and ACES q Exclusion Criteria: * Individuals who meet for PTSD diagnosis from a criterion A trauma occurring in adulthood without a history of ELA * Individuals experiencing active mania or psychosis * Individuals with an active substance use disorder * Individuals presenting with active suicide risk (plan, intention, means) indicative of a need for higher level care * Individuals in current psychotherapeutic treatment (defined as having engaged in consistent psychotherapy within the last 3 months)
Conditions Postpartum Depression, Breastfeeding, Po...
Phase NA
Enrollment 104
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

This randomized controlled trial aims to evaluate the effect of a midwife-led digital follow-up program on postpartum depression, perceived social support, and breastfeeding self-efficacy in women who will undergo cesarean section. Participants will be randomly assigned to either an intervention group that will receive structured face-to-face education followed by a 4-week digital follow-up program, or a control group that will receive routine postpartum care. Data will be collected at baseline (postpartum day 1), at 1 week, and at 4 weeks postpartum using validated measurement tools. The study will provide evidence on the effectiveness of continuous, midwife-led digital support in improving maternal psychological well-being and breastfeeding outcomes in the early postpartum period.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Midwife-Led Digital Follow-Up Program — Participants will receive a structured face-to-face education session on the first postpartum day followed by a 4-week digital follow-up program including weekly educational messages, individualized counseling, and continuous support via mobile communication platforms.

Primary Outcomes

  • Postpartum Depression (Baseline (first postpartum day), 1 week postpartum, and 4 weeks postpartum)
  • Perceived Social Support (Baseline (first postpartum day), 1 week postpartum, and 4 weeks postpartum)
  • Breastfeeding Self-Efficacy (Baseline, 1 week, and 4 weeks postpartum)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-15
Completion: 2026-10
Eligibility
Age: 18 Years – 45 Years
Sex: FEMALE
Volunteers: false
Enrollment: 104 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Inonu University
Collaborators: Kahramanmaras Sutcu Imam University
Contact Information
Study Contact:
Tuba E Benli
+90 552 456 58 28
enise.benli@giresun.edu.tr
Emel Güçlü Cihan
emelcihan@ksu.edu.tr
Tuba Benli
enise.benli@giresun.edu.tr
Giresun University
Interventions
  • Behavioral: Midwife-Led Digital Follow-Up Program — Participants will receive a structured face-to-face education session on the first postpartum day followed by a 4-week digital follow-up program including weekly educational messages, individualized counseling, and continuous support via mobile communication platforms.
Study Locations (1 sites)
Giresun University, Giresun, 28200 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Women aged between 18 and 45 years * Women who have undergone cesarean section * Within the first 24 hours postpartum * Able to communicate in Turkish * Having a healthy singleton newborn * Willing to participate and provide informed consent Exclusion Criteria: * History of psychiatric disorders * Presence of severe maternal complications * Newborn requiring intensive care unit admission * Women with communication difficulties * Participation in another intervention study
Conditions Schizophrenia and Related Disorders, Maj...
Phase PHASE3
Enrollment 1254
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

Schizophrenia, bipolar and major depressive disorders collectively affect over 10 million people across the EU and are associated with annual healthcare and societal costs in excess of 100 billion Euros. When diagnosed with one of these disorders, patients are prescribed psychotropic medication such as antidepressants, mood stabilisers or antipsychotics. It is unknown whether this first-line treatment will be successful. After this first-line treatment fails, usually a second-line treatment is initiated, and when this is not successful either a third-line treatment is initiated. Third-line treatments are quite successful, especially when compared to second-line treatments. The research question is whether the third-line treatments (early-intensified treatments) when used earlier in the disease course for schizophrenia, bipolar and major depressive disorders. If this is indeed the case, this could lead to the prevention of unnecessary trials of ineffective treatments and adaptations of worldwide guidelines as well as a reduction of healthcare and societal costs.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Drug: Clozapine — See arm description
  • Drug: Esketamine Nasal Product — See arm description
  • Drug: Escitalopram — See arm description
  • Drug: Sertraline — See arm description
  • Drug: Venlafaxine — See arm description
  • Drug: Lithium — See arm description
  • Drug: Valproate acid — See arm description
  • Drug: Quetiapine — See arm description

Primary Outcomes

  • Change in symptom severity (6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-04-27
Completion: 2028-06-30
Eligibility
Age: 18 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 1254 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Dr. Inge Winter
Collaborators: Universität Münster
Contact Information
Study Contact:
Inge Winter, Dr.
+31875553227
i.winter@umcutrecht.nl
Cynthia Okhuijsen-Pfeifer, Dr.
+31875553227
c.pfeifer@umcutrecht.nl
Mark Weiser, MD, PhD
mweiser@netvision.net.il
Sheba Medical Center
Interventions
  • Drug: Clozapine — See arm description
  • Drug: Esketamine Nasal Product — See arm description
  • Drug: Escitalopram — See arm description
  • Drug: Sertraline — See arm description
  • Drug: Venlafaxine — See arm description
Study Locations (1 sites)
Sheba Medical Center, Ramat Gan, Israel
Eligibility Criteria
Inclusion Criteria: 1\. In- or out patients, at least 18 years of age up until 70 (SZ study sample), 65 years (MDD study sample) and no limit for the BD study.. Being willing and able to provide written informed consent. Having a legal guardian to cosign is allowed. Informed consent will be signed at visit 1, before any study procedure. 3\. Female subjects of child bearing potential must be willing to ensure that they use effective contraception during the trial and as per the requirements in the protocol (section 8.2.1).Male subjects that will use valproate acid during the trial must use effective contraceptive measures during the trial. 4\. Meeting diagnostic criteria for a primary diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, major depressive disorder (without psychotic features) or bipolar depression (bipolar disorder type I and II currently in a depressive episode), according to DSM-5. The primary diagnosis will be confirmed by the Mini International Neuropsychiatric Interview (MINI v7.0.2). 5\. Subject experiences a treatment failure due to lack of efficacy in the current episode, as confirmed by a CGI-I ≥3; preferably this treatment is a first-line pharmacotherapeutic agent for the primary DSM-5 diagnosis, and was prescribed for at least 4 weeks within an effective dose range as specified in the Summary of Product Characteristics (SmPCs). However, other lines of treatment are accepted as well. 6\. Subject and clinician intend to change pharmacotherapeutic treatment. 7. A minimum symptom severity threshold needs to be present (moderate level; see below) and subject needs to experience functional impairment. * The minimum symptom severity threshold for SZ subjects is at least 2 PANSS positive or negative items with a score of 4, or at least one PANSS positive or negative item with a score of 5. * The minimum symptom severity threshold for MDD is a score of ≥ 20 on the Montgomery Åsberg Depression Rating Scale (MADRS) * The minimum symptom severity threshold for BD is a score of ≥20 on the Montgomery Åsberg Depression Rating Scale (MADRS) * For all study samples: Functional impairment is defined as a score of 5 or higher on any of the three scales of the Sheehan Disability Scale (SDS). Exclusion criteria: 1. Being pregnant or breastfeeding. 2. Subject has failed previously on the EIPT study medication (i.e. SZ: clozapine; MDD: esketamine intranasal/(es)ketamine IV) Treatment duration as ≥ 4 weeks within an efficacious dose range according to the SmPC. 3. Subject has a known intolerance to clozapine (SZ only), esketamine intranasal/ (es)ketamine IV (MDD only) or quetiapine (BD only) or to all medication options for a study sample (related to the TAU treatment arms) or all EIPT medications (BD study sample). 4. Meeting any of the contraindications of clozapine (SZ only), esketamine intranasal/ (es)ketamine IV (MDD only) or quetiapine (BD only), or to all medication options for a study sample (related to the TAU treatment arms), or all EIPT medications (BD study sample), as specified within the applicable SmPC. 5. Subject has participated in another clinical trial in which the subject received an experimental or investigational drug or agent within 30 days before visit 1. 6. Subject experiences any other significant disease or disorder which, in the opinion of the investigator, may either put the subjects at risk because of participation in the trial, or may influence the result of the trial, or the subject's ability to participate in the trial. 7. 7\. Subjects with active suicidal ideation with some intent to act, without specific plan ("Yes" to question 4 of the Columbia-Suicide Severity Rating Scale (C-SSRS)) or active suicidal ideation with specific plan and intent ("Yes" to question 5 of the C-SSRS), followed by an assessment by the treating clinician who determines it is not safe for the subject to participate in the study 8. Subject meets criteria for current substance use disorder, as confirmed by the Mini International Neuropsychiatric Interview (MINI v7.0.2). Nicotine dependency is allowed, as well as mild and moderate alcohol and/or cannabis use disorder (as defined by MINI v7.0.2). Severe alcohol and/or cannabis use disorder are not allowed. 9. Subjects have not been committed to an institution by virtue of an order issued either by the judicial or the administrative authorities. 10. Subjects dependent on the sponsor, investigator or trial site must be excluded from participation in advance. 11. For the SZ sample only: schizophrenia subjects cannot meet the modified Andreasen criteria for remission. 12. For the SZ sample only: Subjects that have any clinically significant abnormal values on the local laboratory test (especially ANC/WBC and liver values), electrocardiogram (ECG) or physician examinations. 13. For the BD sample only: a score of 12 or higher on the Young Mania Rating Scale (YMRS) in order to exclude subjects with predominant manic symptoms or mixed symptoms. 14. For the BD study sample only: Subjects with a history of antidepressant-induced mania or hypomania or recent rapid cycling (based on the medical file of the potential participant or the clinical judgment of the clinician). 15. For the BD study sample only: Subjects with pre-existing severe liver damage (as tested within the local laboratory test at visit 1).
Conditions Sleep Disturbance, Sleep, Depression, Su...
Phase NA
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to examine the extent to which delivering sleep and circadian focused interventions in addition to evidenced based psychiatric care for depression and suicide risk may contribute to decreasing suicide risk among high risk young adults. Investigators will evaluate three interventions targeting sleep in acutely suicidal college students enrolled in intensive outpatient treatment. Participants will be randomly assigned to one of three intervention groups: 1. Triple Chronotherapy (TCT)+ Transdiagnostic Sleep and Circadian Intervention (TSC) 2. Transdiagnostic Sleep and Circadian Intervention (TSC) 3. Sleep Feedback (SF) Participants will be followed for 6 months with primary outcome domains of suicidal thoughts and behaviors and depression evaluated by blinded clinicians at short (Days 1-4 of intervention), medium (2 months) and long (6 month) term intervals.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Sleep Feedback + Psychoeducation — Participants are provided with an actigraphy watch that is used to monitor their sleep and activity throughout the day and complete a sleep diary daily. Along with wearing the watch they also will be provided access to their actigraphy and sleep diary graphs that document their data on demand via smartphone link.
  • Behavioral: Transdiagnostic Sleep and Circadian Intervention + Bright Light (TSC+) — Behavioral: TSC+ • This intervention includes participants attending 6-8 sessions of a manualized sleep intervention with a Sleep Therapist, delivered in person or videoconference, as well as daily bright light therapy (up to one hour daily) and blue light blocking glasses (up to one hour before bedtime)
  • Behavioral: Triple Chronotherapy (TCT+) — Behavioral: TCT+ • One night of total sleep deprivation followed by three nights of sleep phase advancement in the sleep lab, daily bright light therapy (up to one hour daily) and blue light blocking glasses (up to one hour before bedtime), in a sleep lab.

Primary Outcomes

  • Suicidal Thoughts and Behaviors via CSSRS ((short term) Intervention Days 1-4)
  • Suicidal Thoughts and Behaviors via CSSRS ((medium term) 2 month follow up)
  • Suicidal Thoughts and Behaviors via CSSRS ((long term) 6 month follow up)
  • Suicidal Thoughts and Behaviors via LIFE SI/SIB scale ((medium term) 2mo follow up)
  • Suicidal Thoughts and Behaviors via LIFE SI/SIB scale ((long term) 6mo follow up)
  • Depression via KSADS Depression Rating Scale ((short term) Intervention Days 1-4)
  • Depression via KSADS Depression Rating Scale ((medium term) 2mo follow up)
  • Depression via KSADS Depression Rating Scale ((long term) 6mo follow up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-18
Completion: 2029-03
Eligibility
Age: 18 Years – 25 Years
Sex: ALL
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Pittsburgh
Collaborators: American Foundation for Suicide Prevention
Principal Investigators:
  • Tina Goldstein, PhD (PRINCIPAL_INVESTIGATOR) - University of Pittsburgh
  • Peter Franzen (PRINCIPAL_INVESTIGATOR) - University of Pittsburgh
Contact Information
Study Contact:
Dawn Rice, MS
412-297-1947
ricedm@upmc.edu
Tina Goldstein, PhD
412-246-5604
goldtr@upmc.edu
Dawn Rice, MS
412-297-1947
ricedm@upmc.edu
Western Psychiatric Hospital/University of Pittsburgh
Interventions
  • Behavioral: Sleep Feedback + Psychoeducation — Participants are provided with an actigraphy watch that is used to monitor their sleep and activity throughout the day and complete a sleep diary daily. Along with wearing the watch they also will be provided access to their actigraphy and sleep diary graphs that document their data on demand via smartphone link.
  • Behavioral: Transdiagnostic Sleep and Circadian Intervention + Bright Light (TSC+) — Behavioral: TSC+ • This intervention includes participants attending 6-8 sessions of a manualized sleep intervention with a Sleep Therapist, delivered in person or videoconference, as well as daily bright light therapy (up to one hour daily) and blue light blocking glasses (up to one hour before bedtime)
  • Behavioral: Triple Chronotherapy (TCT+) — Behavioral: TCT+ • One night of total sleep deprivation followed by three nights of sleep phase advancement in the sleep lab, daily bright light therapy (up to one hour daily) and blue light blocking glasses (up to one hour before bedtime), in a sleep lab.
Study Locations (1 sites)
Western Psychiatric Hospital/University of Pittsburgh, Pittsburgh, Pennsylvania 15213 United States
Eligibility Criteria
Inclusion Criteria: * Enrolled or planning to enroll in treatment at COSTAR Intensive Outpatient Program * English language fluency and literacy sufficient to engage in study protocol * Suicidal ideation or suicide attempt in past month * Clinically significant sleep disturbance, operationalized as Pittsburgh Sleep Quality Index global PSQI score \>= 7, and/or delayed bedtimes (\>midnight), and/or \>2 hours in sleep timing variability Exclusion Criteria: * Non-affective psychosis per electronic health record (EHR) review and/or baseline clinical assessment, or symptom severity or psychosocial functioning impairments that preclude participation * Contraindications for either sleep deprivation or bright light therapy (e.g., bipolar disorder; seizure disorder; photosensitizing medication) * Intellectual disability precluding comprehension of study procedures * Evidence of untreated obstructive sleep apnea and/or restless legs syndrome * Life-threatening medical condition requiring immediate treatment (such as cancer; end stage disease) * Pregnancy